Sandoz
- All
- News
-
Aurobindo Pharma Shares Jump 6% After Drug Maker Announces $900-Million US Acquisition
Aurobindo Pharma share price jumped more than 6 per cent in intraday trade with large volumes after the announcement. Aurobindo Pharma said it will acquire the dermatology and oral solids businesses from Sandoz Inc, USA, a unit of Swiss pharmaceutical company Novartis. Aurobindo Pharma said the deal worth $900 million was expected to close in 2019...
-
Aurobindo Pharma Buys Parts Of Sandoz US From Novartis For $900 Million
Novartis AG said on Thursday it would sell the dermatology and generic US oral solids portfolios of Sandoz US to Aurobindo Pharma Ltd for $900 million, as the Swiss drug maker looks to focus on higher growth areas. The deal also includes about 300 products and additional development projects of Sandoz and an additional $100 million in performance...
-
Novartis-GSK Pharma Deal Cleared by CCI
The Competition Commission of India (CCI) has approved a multi-billion dollar deal between global pharma giants GlaxoSmithKline Plc and Novartis, as it does not find the transaction to be anti-competitive in India.
-
US Supreme Court agrees to hear Tevas pharma's appeal
Last year, US Court of Appeals for the Federal Circuit reversed a district court's earlier finding related to Teva's US Patent for the drug.
-
Aurobindo Pharma Shares Jump 6% After Drug Maker Announces $900-Million US Acquisition
Aurobindo Pharma share price jumped more than 6 per cent in intraday trade with large volumes after the announcement. Aurobindo Pharma said it will acquire the dermatology and oral solids businesses from Sandoz Inc, USA, a unit of Swiss pharmaceutical company Novartis. Aurobindo Pharma said the deal worth $900 million was expected to close in 2019...
-
Aurobindo Pharma Buys Parts Of Sandoz US From Novartis For $900 Million
Novartis AG said on Thursday it would sell the dermatology and generic US oral solids portfolios of Sandoz US to Aurobindo Pharma Ltd for $900 million, as the Swiss drug maker looks to focus on higher growth areas. The deal also includes about 300 products and additional development projects of Sandoz and an additional $100 million in performance...
-
Novartis-GSK Pharma Deal Cleared by CCI
The Competition Commission of India (CCI) has approved a multi-billion dollar deal between global pharma giants GlaxoSmithKline Plc and Novartis, as it does not find the transaction to be anti-competitive in India.
-
US Supreme Court agrees to hear Tevas pharma's appeal
Last year, US Court of Appeals for the Federal Circuit reversed a district court's earlier finding related to Teva's US Patent for the drug.
